Top

Published in:

01-11-2018 | Case report

Insulin/insulin-glargine/Insulin-suspension-isophane

Localised insulin-derived amyloidosis: case report

Published in: Reactions Weekly | Issue 1/2018

Excerpt

A 76-year-old woman developed localised insulin-derived amyloidosis (AIns) during treatment with insulin, insulin suspension isophane and insulin glargine for type II diabetes mellitus (DM) [not all durations of treatments to reactions onset stated]. …

Katzman BD, et al. New Histologic Finding of Amyloid Insulin Bodies at an Insulin Injection Site in a Patient With Diabetes. American Journal of Dermatopathology 40: 527-530, No. 7, Jul 2018. Available from: URL: http://doi.org/10.1097/DAD.0000000000001052 - CanadaCrossRef

Title: Insulin/insulin-glargine/Insulin-suspension-isophane
Localised insulin-derived amyloidosis: case report
Publication date: 01-11-2018
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2018
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-54153-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Insulin/insulin-glargine/Insulin-suspension-isophane

Localised insulin-derived amyloidosis: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Kanamycin

Amikacin/clofazimine

Abatacept

Multiple drugs

Methylprednisolone

Apremilast/etanercept/secukinumab